NCT04511624View on ClinicalTrials.gov

Single Dose Tolerability and Pharmacokinetics of IBI112 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

August 27, 2020

Primary Completion Date

July 22, 2022

Study Completion Date

July 22, 2022

Conditions
Healthy Subjects
Interventions
DRUG

IBI112 dose1

Drug: IBI112 SC dose1 Drug:placebo

DRUG

IBI112 dose2

Drug: IBI112 SC dose2 Drug:placebo

DRUG

IBI112 dose3

Drug: IBI112 SC dose3 Drug:placebo

DRUG

IBI112 dose4

Drug: IBI112 SC dose4 Drug:placebo

DRUG

IBI112 dose5

Drug: IBI112 IV dose5 Drug:placebo

DRUG

IBI112 dose6

Drug: IBI112 SC dose6 Drug:placebo

DRUG

IBI112 dose7

Drug: IBI112 IV dose7 Drug:placebo

Trial Locations (1)

Unknown

Huashan Hospital Affiliated to Fudan University, Shanghai

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT04511624 - Single Dose Tolerability and Pharmacokinetics of IBI112 in Healthy Subjects | Biotech Hunter | Biotech Hunter